Thrivent Financial for Lutherans
CRSP icon

Thrivent Financial for Lutherans’s CRISPR Therapeutics CRSP Stock Holding History

Thrivent Financial for Lutherans’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-42,887
Closed -$1.69M – 2388
2024
Q4 		$1.69M Sell
42,887
-4,809
-10% -$227K ﹤0.01% 1566
2024
Q3 		$2.24M Buy
47,696
+473
+1% +$24K ﹤0.01% 1359
2024
Q2 		$2.55M Buy
47,223
+16,051
+51% +$928K 0.01% 1235
2024
Q1 		$2.13M Sell
31,172
-6,751
-18% -$483K ﹤0.01% 1367
2023
Q4 		$2.37M Buy
37,923
+4,137
+12% +$229K 0.01% 1271
2023
Q3 		$1.53M Sell
33,786
-15,017
-31% -$776K ﹤0.01% 1476
2023
Q2 		$2.74M Sell
48,803
-401
-0.8% -$22.8K 0.01% 1138
2023
Q1 		$2.23M Sell
49,204
-29,612
-38% -$1.44M 0.01% 1230
2022
Q4 		$3.2M Buy
78,816
+53,608
+213% +$2.84M 0.01% 973
2022
Q3 		$1.65M Buy
25,208
+4,144
+20% +$300K ﹤0.01% 1339
2022
Q2 		$1.28M Buy
21,064
+9,382
+80% +$552K ﹤0.01% 1545
2022
Q1 		$733K Sell
11,682
-28,702
-71% -$1.8M ﹤0.01% 2006
2021
Q4 		$3.4M Buy
40,384
+38,516
+2,062% +$3.36M 0.01% 1070
2021
Q3 		$209K Sell
1,868
-2,088
-53% -$262K ﹤0.01% 2420
2021
Q2 		$640K Buy
3,956
+1,373
+53% +$167K ﹤0.01% 2092
2021
Q1 		$315K Buy
+2,583
New +$390K ﹤0.01% 2377
2020
Q4 		– Hold
0
– – – 2365

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Thrivent Financial for Lutherans's CRSP Position: Q1 2025 in Review

Thrivent Financial for Lutherans sold out of CRISPR Therapeutics (CRSP) in Q1 2025, closing a stake of 42,887 shares — an estimated $1.69M sold.

Thrivent Financial for Lutherans first reported a position in CRSP in Q1 2021 and held it in 16 quarters. The position peaked at $3.4M in Q4 2021. 396 funds tracked by Wall St. Rank hold CRSP as of Q1 2025.

  • Thrivent Financial for Lutherans reported no remaining CRISPR Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 42,887 CRISPR Therapeutics shares in Q1 2025, an estimated $1.69M.
  • Thrivent Financial for Lutherans first reported a position in CRISPR Therapeutics in Q1 2021 and held it in 16 quarters.
  • Thrivent Financial for Lutherans's CRISPR Therapeutics position peaked at $3.4M in Q4 2021.
  • 396 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2025.

Based on Thrivent Financial for Lutherans's 13F filing for Q1 2025, filed 13 May 2025.